Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity

Immunity. 2008 Jun;28(6):822-32. doi: 10.1016/j.immuni.2008.04.020.

Abstract

The basis for strong immunogenetic associations between particular human leukocyte antigen (HLA) class I allotypes and inflammatory conditions like Behçet's disease (HLA-B51) and ankylosing spondylitis (HLA-B27) remain mysterious. Recently, however, even stronger HLA associations are reported in drug hypersensitivities to the reverse-transcriptase inhibitor abacavir (HLA-B57), the gout prophylactic allopurinol (HLA-B58), and the antiepileptic carbamazepine (HLA-B*1502), providing a defined disease trigger and suggesting a general mechanism for these associations. We show that systemic reactions to abacavir were driven by drug-specific activation of cytokine-producing, cytotoxic CD8+ T cells. Recognition of abacavir required the transporter associated with antigen presentation and tapasin, was fixation sensitive, and was uniquely restricted by HLA-B*5701 and not closely related HLA allotypes with polymorphisms in the antigen-binding cleft. Hence, the strong association of HLA-B*5701 with abacavir hypersensitivity reflects specificity through creation of a unique ligand as well as HLA-restricted antigen presentation, suggesting a basis for the strong HLA class I-association with certain inflammatory disorders.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / immunology
  • Anti-HIV Agents / metabolism
  • Antigen Presentation
  • CD8-Positive T-Lymphocytes / immunology*
  • Dideoxynucleosides / adverse effects*
  • Dideoxynucleosides / immunology
  • Dideoxynucleosides / metabolism
  • Drug Hypersensitivity / immunology*
  • Drug Hypersensitivity / metabolism
  • HLA-B Antigens / chemistry
  • HLA-B Antigens / immunology*
  • HLA-B Antigens / metabolism
  • Humans
  • Lymphocyte Activation*
  • Reverse Transcriptase Inhibitors / adverse effects*
  • Reverse Transcriptase Inhibitors / immunology
  • Reverse Transcriptase Inhibitors / metabolism

Substances

  • Anti-HIV Agents
  • Dideoxynucleosides
  • HLA-B Antigens
  • HLA-B*57:01 antigen
  • HLA-B*57:03 antigen
  • Reverse Transcriptase Inhibitors
  • abacavir